晚期黑色素瘤肝转移患者单用抗PD-1或联合抗CTLA-4治疗
该国际多中心回顾性研究纳入晚期黑色素瘤肝转移一线接受抗PD-1单药或联合抗CTLA-4治疗的患者,中位随访47个月(95%CI 42-51)。联合治疗客观缓解率47%高于单药的35%(p=0.0027),无进展生存和总生存两组间无统计学差异;多变量分析中联合治疗与更高客观缓解(OR 2.21,1.46-3.36;p<0.001)、无进展生存(HR 0.73,0.57-0.92;p=0.009)和总生存(HR 0.71,0.54-0.94;p=0.018)相关。作者认为联合治疗可考虑用于该类患者。
要点
- 肝转移患者联合治疗客观缓解率47% vs 单药35%(p=0.0027)。
- 多变量分析联合治疗与更高缓解(OR 2.21)及更优PFS(HR 0.73)、OS(HR 0.71)相关。
- 作者建议肝转移患者可考虑联合治疗。
核心结论
- 研究结果有助于指导肝转移患者的治疗选择,作者建议该组患者可考虑联合治疗。
研究设计与样本
- 国际多中心回顾性研究,纳入晚期黑色素瘤肝转移一线接受抗PD-1单药或联合抗CTLA-4治疗的患者。
- 研究终点为客观缓解率、无进展生存和总生存。
主要发现
- 中位随访47个月(95%CI 42-51),联合治疗客观缓解率47% vs 抗PD-1单药35%(p=0.0027)。
- 无进展生存和总生存两组间无统计学差异。
- 多变量分析(对缺失值多重插补并校正预设变量)显示联合治疗与更高客观缓解相关(OR 2.21,1.46-3.36;p<0.001)。
- 多变量分析显示联合治疗与更优无进展生存相关(HR 0.73,0.57-0.92;p=0.009)。
- 多变量分析显示联合治疗与更优总生存相关(HR 0.71,0.54-0.94;p=0.018)。
临床怎么用
- 作者认为,对于晚期黑色素瘤肝转移患者,可考虑联合抗PD-1与抗CTLA-4治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The combination of anti-PD-1 and anti-CTLA-4 has been associated with improvement in response and survival over anti-PD-1 monotherapy in unselected patients with advanced melanoma. Whether patients with liver metastases also benefit from the combination of anti-PD-1 and anti-CTLA-4 over anti-PD-1, is unclear. In this study, we sought to assess whether the combination of anti-PD-1 and anti-CTLA-4 leads to better response, progression-free survival and overall survival, compared with anti-PD-1 monotherapy for patients with liver metastases. METHODS: We have conducted an international multicentre retrospective study. Patients with advanced melanoma with liver metastases treated with 1st line anti-PD1 monotherapy or with anti-CTLA-4 were included. The endpoints of this study were: objective response rate, progression-free survival and overall survival. RESULTS: With a median follow-up from commencement of anti-PD-1 monotherapy or in combination with anti-CTLA-4 of 47 months (95% CI, 42-51), objective response rate was higher with combination therapy (47%) versus anti-PD-1 monotherapy (35%) (p = 0.0027), while progression-free survival and overall survival were not statistically different between both treatment groups. However, on multivariable analysis with multiple imputation for missing values and adjusting for predefined variables, combination of anti-PD1 and anti-CTLA-4 was associated with higher objective response (OR 2.21, 1.46 - 3.36; p < 0.001), progression-free survival (HR 0.73, 0.57 - 0.92; p = 0.009) and overall survival (HR 0.71, 0.54 - 0.94; p = 0.018) compared to anti-PD1 monotherapy. CONCLUSIONS: Findings from this study will help guide treatment selection for patients who present with liver metastases, suggesting that combination therapy should be considered for this group of patients.
引用
- Pires da Silva I, Li I, Ugurel S, et al. Anti-PD-1 alone or in combination with anti-CTLA-4 for advanced melanoma patients with liver metastases. Eur J Cancer. 2024. PMID: 38735161. doi:10.1016/j.ejca.2024.114101
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。